Skip to main content

Table 3 Subgroup analysis of prognostic factors

From: Combined score of pretreatment platelet count and CA125 level (PLT-CA125) stratified prognosis in patients with FIGO stage IV epithelial ovarian cancer

Groups PLT-CA125 N (%) OS (months) PFS (months)
Median (SD) 95% CI p Median (SD) 95% CI p
FIGO stage
 IVA 0 5 (29.4) 48.3 (14.6) 19.6–77.0 0.600 11.17   0.185
1 7 (41.2) 47.4 (13.4) 21.1–73.7   31.8 (13.6) 5.14–58.5  
2 5 (29.4) 41.7 (10.1) 21.9–61.5   13.3 (5.59) 2.32–24.2  
 IVB 0 34 (37.4) 90.4 (18.9) 53.2–127.6 0.003 32.0 (4.37) 23.4–40.6 0.107
1 41 (45.1) 42.7 (2.99) 36.8–48.5   20.0 (3.12) 13.9–26.1  
2 16 (17.6) 37.8 21.2–54.4   19.7 (3.15) 13.5–25.8  
Age
  < 55 0 19 (32.8) 90.4 (29.2) 33.2–147.6 0.003 35.4 (8.95) 17.9–52.9 0.101
1 25 (43.1) 42.7 (0.71) 41.3–44.1   21.0 (2.89) 15.4–26.6  
2 14 (24.1) 40.7 (8.2) 24.7–47.1   16.2 (3.98) 8.43–24.0  
55 0 20 (40.0) 70.0 (13.0) 44.6–95.4 0.183 32.0 (6.29) 19.7–44.3 0.404
1 23 (46.0) 28.7 (9.13) 10.8–46.6   16.9 (5.01) 7.11–26.7  
2 7 (14.0) 37.8 (8.34) 21.5–54.1   23.9 (3.45) 18.2–28.4  
Histology
 HGSC 0 29 (34.1) 111.6 (26.6) 59.4–163.8 0.002 35.4 (4.45) 26.69–44.1 0.021
1 39 (45.9) 42.7 (4.88) 33.1–52.2   20.0 (4.61) 10.9–29.0  
2 17 (20.0) 41.7 (2.77) 36.3–47.1   21.5 (2.82) 18.9–27.0  
 Non-HGSC 0 10 (43.5) 20.4 (20.5) 0.00–60.5 0.189 9.57 (11.4) 0.00–31.9 0.117
1 9 (38.3) 43.2 (5.55) 32.3–54.1   33.5 (15.8) 2.52–64.5  
2 4 (17.4) 15.6    8.83 (2.08) 4.75–12.9  
Primary treatment
 PDS + chemotherapy 0 21 (39.6) 90.4 (31.5) 28.7–152 0.009 40.1 (3.71) 32.8–47.3 0.104
1 24 (45.3) 42.7 (6.04) 30.8–54.5   21.1 (4.42) 12.4–29.8  
2 8 (15.1) 40.7 (15.7) 9.87–71.5   17.5 (5.47) 6.79–28.25  
 NACT+IDS/ Chemotherapy alone 0 18 (32.7) 70.0 (29.1) 12.9–127 0.254 23.3 (4.97) 13.6–33.0 0.571
1 24 (45.3) 43.2 (3.87) 35.6–50.8   20.0 (2.68) 14.74–25.26  
2 13 (23.6) 37.8 (7.67) 22.8–52.8   19.7 (4.46) 10.9–28.4  
Surgery
 Optimal surgery 0 30 (36.6) 80.4 (20.2) 50.8–130 0.003 32.0 (6.14) 19.9–44.0 0.167
1 35 (42.7) 43.9 (3.21) 37.6–50.2   23.6 (6.23) 11.4–35.8  
2 17 (20.7) 40.7 (10.2) 20.8–60.6   21.5 (6.07) 11.6–31.4  
 Suboptimal surgery/no surgery 0 9 (34.6) 45.7 (23.6) 0.00–91.86 0.175 35.4 (17.4) 1.37–69.5 0.046
1 13 (50.0) 23.2 (13.5) 0.00–49.7   12.8 (4.26) 4.49–21.2  
2 4 (15.4) 37.8 (12.4) 13.6–62.0   12.6 (4.68) 3.44–21.8  
  1. Abbreviations: PLT platelet, OS overall survival, PFS Progress-free survival, SD standard deviation, CI confidence interval, HGSC high grade serous carcinoma, Non-HGSC non-high grade serous carcinoma, PDS primary debulking surgery, NACT neoadjuvant chemotherapy, IDS interval debulking surgery, LNM lymph nodes metastasis beyond abdominopelvic cavity